According to an official involved in the talks, the EU could pay more than $10 billion to secure hundreds of millions of doses of COVID-19 vaccines being developed by Pfizer-BioNTech and CureVac, as reported in Fidelity.
The official said the bloc has agreed to pay €15.50 per dose for the vaccine being developed by Pfizer and BioNTech
That would mean an overall price of up to €3.1 billion for 200 million doses, rising to €4.65 billion if another optional 100 million doses are purchased under the deal, the source said.
The official noted that in a separate deal, the EU has agreed to pay €10 per dose for an initial supply of 225 million doses of CureVac's candidate, a discount from the €12 the company had set as the price.
The bloc struck the deal with CureVac this week to secure the supply of up to 405 million doses, of which 180 million are optional.
The official said CureVac had committed to starting deliveries by the end of March, although it is unclear whether the additional 180 million doses would cost €10 or €12 each. At €10 per dose, the bloc would pay €4.05 billion for 405 million doses.
To read more NewsPoints articles, click here.